Primary sclerosing cholangitis

A Stiehl MD, C Benz MD, P Sauer MD

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by fibrosing inflammation and obliteration of intra- and/or extrahepatic bile ducts. The disease is one of the most common cholestatic diseases in adults and is diagnosed with increasing frequency. It is very often associated with ulcerative colitis. Patients with PSC have an increased incidence of bile duct carcinomas, and those with ulcerative colitis also have an increased incidence of colonic carcinomas.

In end-stage disease, liver transplantation is the treatment of choice. Immunosuppressive treatment has little effect. Ursodeoxycholic acid (UDCA), which has been shown to improve liver histology and survival in patients with primary biliary cirrhosis, has a beneficial effect in PSC, provided that patients who develop major duct stenoses are treated endoscopically. The aim is to treat patients as early as possible to prevent progression to the advanced stages of the disease. During treatment with UDCA, stenoses of major ducts may develop, and early endoscopic dilatation is highly effective. Because UDCA treatment improves but does not cure cholestatic liver diseases, permanent treatment seems to be necessary. Such prolonged treatment with UDCA may be recommended because, until now, no side effects have been reported. In patients with end-stage disease, UDCA is not effective and liver transplantation is indicated.

Key Words: Cholestatic liver disease; Primary sclerosing cholangitis; Ursodeoxycholic acid

Cholangite sclérosante primitive


Le traitement à privilégier dans les cas de maladie terminale est la transplantation du foie. Le traitement immunosuppresseur ne produit guère d’effets. L’acid ursodéoxycholique (AUDC), qui a déjà montré sa capacité d’améliorer l’histologie du foie et la survie des patients atteints de cirrhose biliaire primitive, s’avère salutaire chez les patients souffrant de CSP, pourvu que les sténoses importantes des voies biliaires soient traitées par endoscopie. Le but est de traiter les patients le plus tôt possible pour prévenir l’évolution de la maladie vers des stades avancés. Toutefois, le traitement à l’AUDC peut entraîner une sténose des principales voies biliaires, mais leur dilatation endoscopique s’avère une intervention très efficace. Comme le traitement à l’AUDC soulage mais ne guérit pas les maladies cholestatiques du foie, il semble que les patients doivent le suivre indefiniment. Il peut être prescrit à long terme parce que, jusqu’à maintenant, aucun effet secondaire n’a été signalé. Par contre, l’AUDC est sans effet chez les patients rendus au stade terminal de la maladie, et la transplantation du foie est indiquée.

The serum marker perinuclear antineutrophil cytoplasmic antibody has been detected in up to 85% of patients with PSC, but the marker is not specific for the disease and may be positive in patients with ulcerative colitis without PSC (10). The frequency of human leukocyte antigens (HLA) -B8 and -DR3 is higher in PSC patients than in controls (60% to 80% versus 20% to 30% in controls). HLA-B8 and HLA-DR3 are found in various autoimmune diseases, and their presence is suggestive of immunological factors involved in...
PSC. There is no reliable serum marker with sufficient sensitivity and specificity to allow the early diagnosis of PSC.

The disease in general is diagnosed by endoscopic retrograde cholangiography, which shows multiple intra- and/or extrahepatic stenoses with prestenotic dilations that give the biliary system its typical appearance (1-9). In some patients, major prestenotic cavities of the bile ducts may develop. Due to the multiple stenoses and prestenotic dilations of the biliary tree, patients tend to have repeated episodes of bacterial cholangitis. Because PSC is a focal disease, the typical fibroising inflammation around the bile ducts may be missed in a single liver biopsy. Accordingly, liver biopsy allows the histological staging but is of limited value in the detection of the disease.

The prevalence of PSC has been estimated to be five to 10 per 100,000. Approximately 70% to 90% of patients with PSC have inflammatory bowel disease, and 5% to 10% of patients with ulcerative colitis have PSC (11). Of 1500 Swedish patients with ulcerative colitis, 72 had an elevated AP level, and of those, 85% had PSC (12). In this study, the prevalence of PSC in patients with colitis was 5.5%, and the prevalence of colitis in PSC patients was 90%. As a consequence, an endoscopic retrograde cholangiopancreatography should be performed in all patients with inflammatory bowel disease with an elevated serum AP level; this will allow the majority of patients with PSC to be detected.

**BILE DUCT CARCINOMA**

An unresolved problem in the treatment of patients with PSC is the development of bile duct carcinomas (3-9). Until now, it has been very difficult to detect cholangiocarcinomas at an early stage. Brush border cytology of dominant strictures is of limited sensitivity (13). The tumour markers carcinoembryonic antigen and carbohydrate antigen 19.9 are neither sensitive nor specific (14). Imaging methods (computed tomography, nuclear magnetic resonance) do not allow the detection of early carcinomas, and the results with positron emission tomography (15) need confirmation in larger trials. When the carcinoma has developed, the prognosis in general is very poor.

In a large multicentre study from Sweden in which 305 PSC patients were followed for a median of 63 months, a bile duct carcinoma was observed in 8% of patients; 44% of these patients were asymptomatic at the time of diagnosis of PSC (12). In 37% of the patients, bile duct carcinoma was diagnosed within one year after detection of PSC; therefore, it seems possible that the patients already had the bile duct carcinoma when the PSC was recognized. This study is the largest series available, and no factors were found that would allow the identification of patients who would later develop a bile duct carcinoma.

The 8% rate of carcinomas in the Swedish multicentre study is similar to the figure reported by several centres (3-9) and is much lower than that observed by others (7,8). Of interest, in the Swedish study, only 8% of patients developed a cholangiocarcinoma, and 30% of patients with end-stage disease who were considered for transplantation had bile duct carcinomas (12). These data explain why the incidences of bile duct carcinoma from transplantation centres are always much higher than the corresponding figures from prospective studies from gastroenterology units. Very high rates of bile duct carcinomas have repeatedly been reported in studies from transplantation centres (16); it appears that they reflect very selected patient groups.

**COLONIC CARCINOMA**

Colorectal carcinoma occurs more frequently in patients with chronic inflammatory bowel disease than in the normal population. Risk factors are involvement of the whole colon and long duration of the disease. PSC has been shown to be an independent risk factor for the development of colonic carcinoma (17). In a study in which 40 patients with PSC and colitis were matched with 40 patients with the same age, comparable colitis and comparable duration of the disease, the absolute cumulative risk of developing colorectal dysplasia or carcinoma in the patients with PSC was almost five times higher than that in the patients without PSC. The study indicates also that patients with PSC and colitis who develop colonic dysplasia or carcinoma are at a high risk of developing cholangiocarcinoma. It is evident that patients with PSC and colitis need colonoscopic surveillance at short intervals.

**SURVIVAL**

The median length of survival from diagnosis ranges from nine to 12 years (3-9). The survival in asymptomatic patients is longer than that of symptomatic patients (6). At the time of diagnosis, many patients are asymptomatic and later develop fatigue, pruritus and jaundice. There is no correlation between the severity of PSC and that of ulcerative colitis.

Several survival models have been used to predict the outcome in PSC. In a survival model based on data of five referral centres, age, serum bilirubin and hemoglobin levels, hepatic histological stage and splenomegaly adversely affected survival (18). The aim of such survival models, which were evaluated retrospectively, was to predict the optimal time of liver transplantation. For practical purposes, however, the value of these survival models seems of only limited value because of the great variability of the disease in the individual patient.

**TREATMENT**

Treatment of PSC patients with immunosuppressive, anti-inflammatory or antifibrotic agents has not been successful. Reports on a beneficial effect of methotrexate need confirmation in controlled trials (19). Because repeated episodes of bacterial cholangitis are typical for the disease, immunosuppressive treatment may even be harmful. The major breakthrough came with the observation that ursodeoxycholic acid (UDCA) has a beneficial effect in patients with primary biliary cirrhosis (PBC) (20-26). Subsequently, patients with various forms of cholestatic liver diseases, including PSC, have been treated with UDCA.
(27-30). That stenoses of the major bile ducts cannot be treated with UDCA and need endoscopic treatment presents a problem.

**EFFECT OF UDCA ON LABORATORY PARAMETERS**

Stimulated by the report of a beneficial effect of UDCA in primary biliary cirrhosis (PBC), in 1987 we started a trial in patients with PSC (27). A double-blind, placebo controlled study was initiated after one year of treatment with UDCA, which demonstrated beneficial effects similar to those seen in patients with PBC and was well tolerated in patients with additional ulcerative colitis. UDCA led to significant improvement of AP, GGT, alanine aminotransferase and aspartate aminotransferase levels. The changes are similar to those seen in three other controlled studies (Table 2) in which serum bilirubin also improved significantly (28-30). Serum cholesterol levels decreased in patients with elevated levels before treatment and were unchanged in the others (27). Changes in immunoglobulin (Ig) A, IgM, and IgG were not significant. Following UDCA, biliary secretion of bile acids, phospholipids and cholesterol increased significantly (31).

In a further controlled study using a relatively low dose of UDCA (600 mg/day), no improvement of laboratory parameters was observed (32), indicating that such a low dose is ineffective. Moreover, a recent placebo controlled study from the United Kingdom showed that UDCA doses of 20 mg/kg significantly improved liver histology, whereas in the same centre, a dose 10 mg/kg, which had been used previously, was ineffective. Cholestasis leads to the decreased absorption of UDCA (33), which may account for the fact that high doses of UDCA are needed for the treatment of PSC. The minimal dose of UDCA that should be recommended in PSC is 15 mg/kg; 20 mg/kg may be even more effective.

**EFFECT OF UDCA ON SYMPTOMS**

Patients with PSC in part suffer from pruritus and fatigue (1-9). During treatment with UDCA, both symptoms improved in some patients, but the effect was not significant compared with placebo (27).

---

**TABLE 1**

<table>
<thead>
<tr>
<th>Author, reference (year)</th>
<th>Follow-up (years)</th>
<th>CA (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaaland et al, 3 (1987)</td>
<td>4.7 (mean)</td>
<td>10</td>
</tr>
<tr>
<td>Helberg et al, 4 (1987)</td>
<td>4.7 (mean)</td>
<td>10</td>
</tr>
<tr>
<td>Lebordics et al, 5 (1987)</td>
<td>4.7 (mean)</td>
<td>0</td>
</tr>
<tr>
<td>Heimann et al, 6 (1988)</td>
<td>8.3 (mean)</td>
<td>4</td>
</tr>
<tr>
<td>Wiesner et al, 7 (1989)</td>
<td>6 (mean)</td>
<td>19</td>
</tr>
<tr>
<td>Farrant et al, 9 (1991)</td>
<td>5.8 (median)</td>
<td>6</td>
</tr>
<tr>
<td>Broome et al, 12 (1996)</td>
<td>5.2 (median)</td>
<td>8</td>
</tr>
<tr>
<td>Stiel et al, 34 (1997)</td>
<td>4.3 (median)</td>
<td>3*</td>
</tr>
</tbody>
</table>

*Patients treated with ursodeoxycholic acid

---

**TABLE 2**

<table>
<thead>
<tr>
<th>Author, reference (year)</th>
<th>AP, GGT, ALT or AST</th>
<th>Bilirubin</th>
<th>Histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stiel et al, 27 (1994)</td>
<td>Improved</td>
<td>Unchanged</td>
<td>Favourable*</td>
</tr>
<tr>
<td>Beuven et al, 28 (1992)</td>
<td>Improved</td>
<td>Unchanged</td>
<td>Favourable</td>
</tr>
<tr>
<td>Lindor, 29 (1997)</td>
<td>Improved</td>
<td>Unchanged</td>
<td>Favourable</td>
</tr>
<tr>
<td>Mitchell et al, 30 (1997)</td>
<td>Improved</td>
<td>Favourable</td>
<td></td>
</tr>
</tbody>
</table>

*Favourable effect compared with pretreatment histology. AP Alkaline phosphatase; ALT Alanine aminotransferase; AST Aspartate aminotransferase; GGT Gamma glutamyl transpeptidase

---

**TABLE 3**

<table>
<thead>
<tr>
<th>Author, reference (year)</th>
<th>Stent</th>
<th>Dilation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johnson et al, 36 (1987)</td>
<td>11</td>
<td>24</td>
</tr>
<tr>
<td>Lee et al, 41 (1995)</td>
<td>22</td>
<td>31</td>
</tr>
<tr>
<td>van Milligen et al, 41 (1996)</td>
<td>21</td>
<td>0</td>
</tr>
<tr>
<td>Stiel et al, 34 (1997)</td>
<td>5</td>
<td>91</td>
</tr>
</tbody>
</table>

---

**EFFECT OF UDCA ON LIVER HISTOLOGY**

In three of four studies in which changes in liver histology were evaluated after UDCA treatment, cellular infiltrates in the portal triads decreased significantly, whereas all other changes were not significant (27,28,30). In one study, no effect of UDCA treatment on liver histology was observed (29). UDCA most efficiently improved liver histology in a very recent study in which a very high dose of UDCA (20 mg/kg) was administered. It is unclear whether a decrease of the inflammation around the bile ducts in PSC affects the development of bile duct carcinomas in this disease. In the placebo group of one controlled study, three of 53 patients developed a bile duct carcinoma, and in the group treated with UDCA, none of 52 patients developed bile duct carcinoma (29). The tendency in this study in which the patients were treated for two to five years is of interest. Longer lasting trials are necessary to answer the question of whether UDCA can reduce the incidence of cholangiocarcinomas definitely.

**STENOSSES OF MAJOR BILE DUCTS DURING UDCA**

In a prospective trial on the effect of UDCA on bile duct disease in which repeat cholangiographies were performed (34) during treatment with UDCA, 10 of 65 patients treated for up to eight years (mean 45 months) developed progressive stenosis of major bile ducts. Endoscopic dilation of these stenosis is highly effective (Table 3) (34-42). Repeat cholangiography in patients with narrowing of major bile ducts
seems essential to detect stenoses of major bile ducts early (34). It is evident that mechanical obstruction of major bile ducts cannot be treated by UDCA effectively and that endoscopic measures are essential if conservative treatment is to be effective.

**EFFECT OF UDCA ON SURVIVAL**

In a controlled two-year study (29) in which endoscopic treatment of major duct stenoses did not play a role, UDCA treatment did not improve survival without liver transplantation. This is in contrast to findings of a prospective, nonrandomized study, in which 65 patients were treated with UDCA and whenever necessary by additional endoscopic dilations from May 1987 to December 1995 (34). The actuarial Kaplan Meier estimate of survival after treatment with UDCA and dilation of major duct stenoses improved significantly compared with the predicted survival (P<0.001) (34).

Liver transplantation significantly improves survival compared with the predicted survival. According to the European Transplant Registry of 1995, of 675 patients who underwent transplantsations for end-stage PSC, 72% were alive after five years. In centres where early transplantation is recommended, the survival rate in patients with PSC and colitis has been reported to be approximately 80% after five and 70% after eight years (43). In view of the fact that the incidence of bile duct carcinomas is much lower than the lethality after transplantation, we do not think that it is justified to recommend prophylactic liver transplantation in precirrhotic stages of the disease to prevent the development of bile duct carcinomas. In a study that is currently being conducted at our institution, all patients with stages 1 to 2 liver disease treated with UDCA and, whenever necessary, by endoscopic means are alive at 12 years without liver transplantation. Therefore, it seems very questionable whether the recommendation of early transplantation is justified.

**CONCLUSIONS**

PSC may be treated conservatively by UDCA with good treatment results and prolongation of survival without liver transplantation only when patients who develop major duct stenoses are recognized early and are additionally treated by endoscopic means. Liver transplantation is indicated for end-stage disease.

**REFERENCES**

32. De Maria N, Colanoni A, Rosenboom E, Van Thiel DH. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period. Hepatogastroenterology 1996;43:1472-79.